Brief: AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
12/08/2025 12:31
Aug 12 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS COMMENCES FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL AN2-502998 FOR CHAGAS DISEASE AN2 THERAPEUTICS - PHASE 2 PLANNING UNDERWAY WITH DNDI COLLABORATION; INITIATION EXPECTED IN 2026, DATA IN 2027 Source text: ID:nBwbvHQmFa Further company coverage: ANTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview